Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06179160 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
A Phase 1 study of Solid Tumors, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 710
- Enrollment target
- 20
- Study locations
NCT06179160: Recruiting Phase 1 study of Solid Tumors, sponsored by Incyte Corporation.
NCT06179160 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 710 participants, above the 279-participant average among 125 other Solid Tumors trials with a reported enrollment target (154% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06179160, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 710 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Primary Outcome
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.
Conditions Studied
Interventions
- DRUG Retifanlimab
- DRUG Cetuximab
- DRUG mFOLFIRINOX
- DRUG INCB161734
- DRUG GEMNabP
Study Locations (20)
California
- Stanford University - Palo Alto
- UCLA Healthcare Hematology-Oncology - Santa Monica
New York
- Weill Cornell Medicine - New York
- Memorial Sloan Kettering Cancer Center - New York
New South Wales
- Chris Obrien Lifehouse - Camperdown
- St Vincent'S Hospital Sydney - Darlinghurst
Victoria
- The Alfred Hospital - Melbourne
- Peter Maccallum Cancer Centre - North Melbourne
Other
- Cliniques Universitaires Ucl Saint-Luc - Brussels
- Universitair Ziekenhuis Antwerpen (Uza) - Edegem
Arizona
- Mayo Clinic Hospital - Phoenix
Colorado
- Sarah Cannon Research Institue At Healthone - Denver
Florida
- Florida Cancer Specialists - Sarasota
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2024-01-04 |
| Est. Completion | 2027-01-01 |
| Phase | Phase 1 |
What NCT06179160 shows while recruiting
NCT06179160 is an interventional study that assigns participants to a tested intervention. The registered 710 participants enrollment target is mid-sized for trials with a published cap, above the 279-participant average among 125 other Solid Tumors trials with a reported enrollment target (154% higher).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Retifanlimab is the first listed.
NCT06179160 names 20 study sites across 15 states, led by California, New York, New South Wales.
Frequently Asked Questions
What is clinical trial NCT06179160 about?
NCT06179160 is a clinical study titled "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation". This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
What is the current status of trial NCT06179160?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 710 participants. The study started on 2024-01-04. Estimated completion is 2027-01-01.
What conditions does trial NCT06179160 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT06179160?
The interventions under investigation include: Retifanlimab (DRUG), Cetuximab (DRUG), mFOLFIRINOX (DRUG), INCB161734 (DRUG), GEMNabP (DRUG).
Who is sponsoring clinical trial NCT06179160?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06179160 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06179160's enrollment target sits among peer trials
710 6th of 125 higher than 120 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI